THE PLACE OF SURGERY IN MODERN TREATMENT OF SKIN MELANOMA

Recent breakthroughs in the treatment of melanoma are associated with the systemic therapy by drugs of new classes, however, the place of surgery remains to be the main in the management of both localized and widespread melanoma. In this literature review, there are systematized the modern concepts of local excision of the primary tumor, the value of biopsy of sentinel lymph node and possibilities of surgical treatment of distant metastases of melanoma.

Download Full-text

The feasibility of sentinel lymph node biopsy in breast cancer patients after primary systemic therapy

Geburtshilfe und Frauenheilkunde ◽

10.1055/s-0028-1088683 ◽

2008 ◽

Vol 68 (S 01) ◽

Author(s):

R Reitsamer ◽

C Menzel ◽

S Glück ◽

E Schlederer ◽

C Wilhelm ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Cancer Patients ◽

Systemic Therapy ◽

Lymph Node Biopsy ◽

Breast Cancer Patients ◽

Primary Systemic Therapy ◽

Node Biopsy

Download Full-text

Sentinel lymph node in cervical cancer: a literature review on the use of conservative surgery techniques

Minerva Ginecologica ◽

10.23736/s0026-4784.20.04634-1 ◽

2021 ◽

Vol 72 (6) ◽

Author(s):

Francesco Plotti ◽

Giuseppe Messina ◽

Corrado Terranova ◽

Roberto Montera ◽

Carlo De Cicco Nardone ◽

...

Keyword(s):

Cervical Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Literature Review ◽

Conservative Surgery

Download Full-text

Sentinel lymph node biopsy in patients with Stage I/II melanoma: Clinical experience and literature review

Journal of Surgical Oncology ◽

10.1002/jso.20026 ◽

2004 ◽

Vol 85 (3) ◽

pp. 133-140 ◽

Cited By ~ 20

Author(s):

Marco Gipponi ◽

Carmine Di Somma ◽

Alberto Peressini ◽

Nicola Solari ◽

Sara Gliori ◽

...

Keyword(s):

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Literature Review ◽

Clinical Experience ◽

Lymph Node Biopsy ◽

Stage I ◽

Node Biopsy

Download Full-text

Sentinel lymph node identification in a primary ductal carcinoma arising in the vulva

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2007.00817.x ◽

2007 ◽

Vol 17 (2) ◽

pp. 471-477 ◽

Cited By ~ 8

Author(s):

J. M. Martinez-Palones ◽

A. Perez-Benavente ◽

B. Diaz-Feijoo ◽

A. Gil-Moreno ◽

I. Roca ◽

...

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Local Excision ◽

World Literature ◽

Ductal Carcinoma ◽

Rare Event ◽

Surgical Specimen ◽

Sentinel Lymph Node Identification ◽

Inguinofemoral Lymphadenectomy

Primary or metastasic breast-like carcinoma of the vulva is a rare event. Because of the similarity with breast ductal carcinoma, we think that the same principles used for treatment of orthotopic breast cancer can be applied, as well as the use of sentinel lymph node technique, which is widely accepted in the management of early-stage breast cancer. We report a 49-old-year postmenopausal woman who was referred to our institution after small biopsy of a 3.5- × 3-cm right vulvar tumor. Histopathologically, infiltration of the vulvar dermis by a ductal carcinoma of mammary gland type was reported. At operation, the sentinel node technique revealed two sentinel nodes in the right inguinal area. Although these nodes proved negative for malignancy, the patient underwent wide local excision of tumor and complete ipsilateral inguinofemoral lymphadenectomy. The remaining excised nodes were negative. Surgical specimen proved estrogen- and progesterone-positive receptors, the reason for which the patient received tamoxifen adjuvant therapy. This report represents the first case in the world literature of primary breast carcinoma arising in the vulva in which sentinel lymph node identification has been possible. Because of the rarity of this condition, the pathologic similarity of this tumor along with currently accepted guidelines for the management of breast cancer supports the possibility of local excision and sentinel lymph node identification as a possible alternative to inguinofemoral lymphadenectomy

Download Full-text

Prostate-specific membrane antigen (PSMA) fusion imaging in prostate cancer: PET/CT vs PET/MRI

British Journal of Radiology ◽

10.1259/bjr.20210728 ◽

2021 ◽

Author(s):

Feng-Yuan Liu ◽

Ting-Wen Sheng ◽

Jing-Ren Tseng ◽

Kai-Jie Yu ◽

Ke-Hong Tsui ◽

...

Keyword(s):

Prostate Cancer ◽

Lymph Node ◽

Local Recurrence ◽

Cancer Patients ◽

Primary Tumor ◽

Tumor Staging ◽

Distant Metastases ◽

Local Tumor ◽

Pet Ct ◽

Primary Tumor Detection

Objectives: To investigate whether PET/CT or PET/MRI is more appropriate for imaging prostate cancer, in terms of for primary tumor detection, local staging and recurrence, as well as lymph nodes and distant metastases. Methods: A systematic literature search was conducted on Embase, PubMed/MEDLINE, and the Cochrane Library database. Studies evaluating the diagnostic performance of PET/CT vs PET/MRI in prostate cancer patients were emphasized. Results: We reviewed 57 original research articles during the period 2016—2021: 14 articles regarding the radiotracer PSMA; 18 articles regarding the primary tumor detection, local tumor staging, managing local recurrence; 17 articles for managing lymph node metastases; and eight articles for managing bone and other distant metastases. PSMA PET could be complementary to mpMRI for primary prostate cancer localization and is particularly valuable for PI-RADS three lesions. PET/MRI is better than PET/CT in local tumor staging due to its specific benefit in predicting extracapsular extension in MRI-occult prostate cancer patients. PET/MRI is likely superior as compared with PET/CT in detecting local recurrence, and have slightly higher detection rates than PET/CT in lymph node recurrence. PET/CT and PET/MRI seem to have equivalent performance in detecting distant bony or visceral metastases. Conclusion: In conclusion, PET/MRI is suitable for local and regional disease, either primary staging or restaging whereas PET/CT is valuable for managing distant bony or visceral metastasis. Advances in knowledge: We reviewed the emerging applications of PET/MRI and PET/CT in clinical aspects. Readers will gain an objective overview on the strength and shortfalls of PET/MRI or PET/CT in the management of prostate cancer.

Download Full-text

Avoiding Axillary Sentinel Lymph Node Biopsy after Neoadjuvant Systemic Therapy in Breast Cancer: Rationale for the Prospective, Multicentric EUBREAST-01 Trial

Cancers ◽

10.3390/cancers12123698 ◽

2020 ◽

Vol 12 (12) ◽

pp. 3698

Author(s):

Toralf Reimer ◽

Aenne Glass ◽

Edoardo Botteri ◽

Sibylle Loibl ◽

Oreste D. Gentilini

Keyword(s):

Breast Cancer ◽

Lymph Node ◽

Sentinel Lymph Node ◽

Sentinel Lymph Node Biopsy ◽

Systemic Therapy ◽

Lymph Node Biopsy ◽

Biological Behavior ◽

Axillary Surgery ◽

Node Biopsy ◽

Neoadjuvant Systemic Therapy

Currently, axillary surgery for breast cancer is considered only as staging procedure, since the risk of developing metastasis depends on the biological behavior of the primary. The postsurgical therapy should be considered on the basis of biologic tumor characteristics rather than nodal involvement. Improvements in systemic treatments for breast cancer have increased the rates of pathologic complete response (pCR) in patients receiving neoadjuvant systemic therapy (NAST), offering the opportunity to de-escalate surgery in patients who have a pCR. European Breast Cancer Research Association of Surgical Trialists (EUBREAST)-01 is a clinical trial in which only patients with the highest likelihood of having a pCR after NAST (triple-negative or HER2-positive breast cancer) will be included and type of surgery will be defined according to the response to NAST rather than on the classical T (for tumor size in the breast) and N (for axillary lymph node involvement) status. In the discussed trial, axillary surgery will be eliminated completely (no axillary sentinel lymph node biopsy) for initially clinical node-negative (cN0) patients with radiologic complete remission and a breast pCR in the lumpectomy specimen. The trial design is a multicenter single-arm study with a limited number of patients (n = 267), which might give practice-changing results in a short period of time, sparing the time and the costs of a randomized comparison.

Download Full-text